All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
Impact of donor age on allo-HSCT outcomes: A CIBMTR registry study
Results from a retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) registry study of 7,116 patients, evaluating the impact of donor age on allogeneic hematopoietic stem cell transplantation (allo-HSCT) outcomes in patients receiving haploidentical or human leukocyte antigen (HLA)-mismatched unrelated donor (MMUD) allo-HSCT with post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease (GvHD) prophylaxis, were published in Transplantation and Cellular Therapy by Mehta et al.
Key data: Older MMUDs (≥30 years) exhibited inferior GvHD-free relapse-free survival (GRFS) compared with younger haploidentical donors (<30 years; hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.06–1.36; p = 0.003), with higher risk of treatment-related mortality and Grade 3–4 acute GvHD. Younger MMUDs showed modest GRFS improvement over older haploidentical donors (HR, 0.87; 95% CI, 0.78–0.98; p = 0.02), with reduced acute and chronic GvHD risks.
Key learning: Younger donors, regardless of donor type, are associated with superior allo-HSCT outcomes compared with older donors. Therefore, where feasible, the use of younger donors aged <30 years should be prioritized when choosing between haploidentical donors and MMUDs.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
When would you be most likely to consider prescribing belumosudil third-line and beyond?
